Acute Thrombotic Events Following Feminizing Hormone Therapy
- Funded by Patient-Centered Outcomes Research Institute
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Known Financial Commitments (USD)
$494,296Funder
Patient-Centered Outcomes Research InstitutePrincipal Investigator
MD. Michael GoodmanResearch Location
United States of AmericaLead Research Institution
Emory UniversityResearch Priority Alignment
N/A
Research Category
Epidemiological studies
Research Subcategory
Disease susceptibility
Special Interest Tags
Gender
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Sexual and gender minoritiesUnspecified
Occupations of Interest
Unspecified
Abstract
COVID-19 may affect transgender people more than others. For example, barriers to timely care may delay diagnosis. Also, transgender people who take gender affirming hormone therapy may have a higher risk for blood clots, which are a sign of severe COVID-19. With this enhancement, the research team will use data from health records to Compare rates of COVID-19 testing in transgender men and women by age, race, and ethnicity Determine the number of COVID-19 cases among transgender and cisgender people who were tested Look at the severity of COVID-19 among transgender and cisgender people Assess whether gender-affirming therapy affects how COVID-19 progresses and patient health outcomes